Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes.
暂无分享,去创建一个
A. Kibel | T. Choueiri | G. Sonpavde | J. Garber | M. Preston | D. Kwiatkowski | K. Mouw | H. Rana | M. Mossanen | C. Curran | P. V. Nuzzo | A. Nassar | S. Stokes | N. Martinez-Chanza | Vivek Kumar | D. Freeman
[1] M. Berger,et al. Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] D. Bajorin,et al. BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC). , 2022, Journal of Clinical Oncology.
[3] T. Powles,et al. A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm. , 2022, Journal of Clinical Oncology.
[4] N. Schultz,et al. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Nussbaum,et al. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. , 2020, JAMA oncology.
[6] E. V. Van Allen,et al. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma , 2019, Genetics in Medicine.
[7] Kenneth Offit,et al. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] L. Kiemeney,et al. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. , 2018, European urology.
[9] N. Malats,et al. Bladder Cancer Genetic Susceptibility. A Systematic Review , 2018, Bladder cancer.
[10] Steven J. M. Jones,et al. Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.
[11] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.
[12] P. Kantoff,et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.
[13] G. Parmigiani,et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.
[14] Donavan T. Cheng,et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. , 2016, JAMA oncology.
[15] M. Nilbert,et al. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. , 2015, Urology.
[16] L. Kiemeney,et al. Epidemiology and risk factors of urothelial bladder cancer. , 2013, European urology.
[17] A. Evans,et al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. , 2013, European urology.
[18] L. Kiemeney,et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers , 2010, Journal of Medical Genetics.
[19] C. Engel,et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. , 2009, Gastroenterology.
[20] M. Greene,et al. Familial and genetic risk of transitional cell carcinoma of the urinary tract. , 2008, Urologic oncology.
[21] John D Potter,et al. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. , 2008, JAMA.
[22] N. Malats,et al. Risk of Bladder Cancer Associated with Family History of Cancer: Do Low-Penetrance Polymorphisms Account for the Increase in Risk? , 2007, Cancer Epidemiology Biomarkers & Prevention.
[23] M. Spitz,et al. Bladder cancer risk as modified by family history and smoking , 2006, Cancer.
[24] P. Hartge,et al. Familial and environmental interactions in bladder cancer risk , 1985, International journal of cancer.
[25] H. Lynch,et al. Familial factors in bladder carcinoma. , 1979, The Journal of urology.
[26] D. Lamm,et al. Familial transitional cell carcinoma of the bladder. , 1975, The Journal of urology.
[27] J. Fraumeni,et al. Malignant Bladder Tumors in a Man and His Three Sons , 1967 .